Indoline compound and 5-HT.sub.3 receptor antagonist containing the same as active ingredient
US5677326A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 29, 1996 |
| Grant date | Oct 14, 1997 |
| Priority date | — |
| Expiry date | Mar 29, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Indoline compounds represented by the general formula: ##STR1## wherein R.sup.1 represents the group ##STR2## R.sup.2 represents a phenyl group which may be substituted or an aromatic heterocyclic group, and R.sup.3 represents hydrogen, a halogen, or a lower alkyl group, hydroxyl group, lower alkoxy group, carbamoyl group or lower alkoxycarbonyl group, and physiologically acceptable salts thereof, and their solvates, as well as 5-HT.sub.3 receptor antagonists containing them as effective components. The indoline compounds of the invention have stronger antagonism against intestinal 5-HT.sub.3 receptors than known 5-HT.sub.3 receptor antagonists and also have excellent sustained action, making them useful as prophylactic or therapeutic agents against vomiting or irritancy induced by chemotherapy or radiation, irritable bowel syndrome, diarrhea, and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.